Invitrogen and Applied Biosystems unveil proposed structure

Invitrogen and Applied Biosystems have revealed how the business divisions and executive team will look if the firms’ merger is approved by shareholders and the European Commission.

The new structure would see a combined firm with four business arms, each focussing on a core competency or discipline – molecular biology, genetic systems, cell systems and mass spectrometry.

Invitrogen’s Greg Lucier will be chairman and chief executive officer of the new firm, with Applied Biosystems’ president and chief operating officer Mark Stevenson taking on those roles in the merged company.

If the takeover is given the go-ahead, the companies also plan to name David Hoffmeister of Invitrogen as new chief financial officer, Bernd Brust of Invitrogen as head of global commercial operations and Mark O’Donnell of Applied Biosystems as global operations and services chief.

"The broad capabilities of the new company will enable revolutionary scientific innovation across the spectrum of genomics, next generation sequencing, cell biology and regenerative medicine," Mr Lucier said.

According to the International Herald Tribune, Invitrogen’s proposed takeover of Applied Biosystems is worth around $6.7 billion (3.72 billion pounds).